In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bridge Medical: Oops-less Medicine

Executive Summary

The subject of medical mistakes has drawn increased attention over the last five years, culminating in the November 1999 Institute of Medicine's report, which made front page news and triggered responses from President Clinton and Congress, as well as the medical establishment and the health care industry. Of particular interest to pharmaceutical and medical products companies is the problem of medication errors, which appear to be increasing for a variety of reasons, ranging from the complexities posed by ever-increasing numbers of drugs and delivery regimens, to more basic factors such as indecipherable physician handwriting and the increased pressure resulting from medical staffing reductions. Whatever the cause, one thing is clear: medication errors are a systemic problem not given to any one quick fix. With the potential for errors occurring at every stage of the medication delivery chain--prescribing, processing, dispensing, and administering drugs--there's plenty of room for companies with potential solutions. Yet, existing information and automated drug distribution systems only incidentally address the problem of medication errors. Bridge Medical, a start-up focused exclusively on developing systems to prevent medication errors, is looking to correct mistakes no matter where they originate by concentrating on the final step in the drug delivery process: the patient's bedside. Bridge recently parted ways with its founder, choosing to move in a different direction that will bring it into more direct competition with large health care information technology players. The company is betting that having a technological headstart and being the only pure-play medication-error company will enable it to successfully navigate what is rapidly becoming a crowded and heavily scrutinized market.

You may also be interested in...



CardioNet: The Promise and Perils of Wireless Medicine

CardioNet created the first product in a new category: mobile cardiac outpatient telemetry. By enabling the continuous monitoring of ambulatory patients for up to 30 days, CardioNet proved - and validated in clinical trials - that it could substantially improve the diagnosis of arrhythmias more effectively than what was then the standard of care. In 2009, the company was approaching profitability when the local Medicare carrier upon which its business depends unexpectedly slashed reimbursement for the company's core product. The management of CardioNet is frustrated. CardioNet has tried to do things the right way. The company validated its technology in a 300-patient controlled clinical trial proving superior efficacy against a gold standard in a disease where early and accurate diagnosis can clearly improve outcomes. Clinicians recognize the value of CardioNet's product, as evidenced by the 50% growth in patient volumes the company enjoyed last year, and the 30 to 40% growth it's expecting for this year. Yet the company fights for the recognition of payors, and for its life. Now, in the face of these reimbursement pressures, CardioNet's number one priority is to gain Medicare reimbursement at the national level, at a rate, it hopes, that recognizes both the costs and value of long-term 24/7 ambulatory monitoring, thereby both validating the company's strategy and supporting the development of wireless medicine as a whole.

Coronavirus Update: After 'Warp Speed' Snub, Novavax Awarded US Military Vaccine Deal

Progress for two US-based companies in the race to develop a COVID-19 vaccine.

Topics

Related Companies

UsernamePublicRestriction

Register

AG032844

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel